Historical brief · 2026-11-17

Isomorphic Labs raises record $5B in Series C funding for AI drug discovery

Alphabet-backed AI drug designer Isomorphic Labs has secured $5 billion in a Series C funding round, breaking the record for the largest private fundraise in biotechnology history. The fresh capital will be used to scale its AI simulation models and advance its internal oncology and immunology pipelines toward clinical trials.

Artificial Intelligence
Source image · BioSpace Drug Development

According to BioSpace, AI-driven drug designer Isomorphic Labs has clinched $5 billion in Series C funding, more than doubling its $2.1 billion Series B raised in May and surpassing Altos Labs' previous $3 billion record set in 2022. The round was co-led by Greenoaks and Sequoia Capital, with continued backing from parent company Alphabet.

Founder and CEO Demis Hassabis stated that the new funds will accelerate the company's progress in building foundational biology models and driving therapeutic programs toward clinical trials. Although the company has not yet publicly disclosed any specific clinical assets, it reports having produced preclinical results for internal programs in oncology and immunology, alongside ongoing research partnerships with major pharmaceutical companies like Novartis, Eli Lilly, and Johnson & Johnson.

View selection rationale
Media reportStage not established

Importance 88/100

Signal90Structure90Consequence85Confidence85Momentum85
About this brief
Content type
News summary
Source type
Publisher report
Source published
Process
AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
Verification
The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
Published by
Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
Conflict disclosure
No financial or commercial conflict declared.

Editorial standards → · Corrections →

POLYEMERGENCE / EXPLORE

Keep exploring

Follow the topic, not just the headline.

Explore the Biotech & Programmable Life archive →